Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

402
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
402
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

194
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
194
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

130
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
130
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Inhaled Medications01:23

Inhaled Medications

250
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
250
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategic aggregation: A more equitable approach to creating two-category variables.

Canadian journal of public health = Revue canadienne de sante publique·2026
Same author

The Appropriate Use of High-Flow Nasal Cannula in Bronchiolitis: A Delphi Approach.

Hospital pediatrics·2025
Same author

Integrating Equity, Diversity, and Inclusion Principles Into Qualitative Research Design.

Qualitative health research·2025
Same author

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model.

bioRxiv : the preprint server for biology·2025
Same author

An Online Repository of Teaching Scripts: Leveraging Group Wisdom for Teaching.

The clinical teacher·2025
Same author

A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD.

Blood·2025

Related Experiment Video

Updated: Jun 22, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Addressing high flow overuse in bronchiolitis - Successes and future directions.

Taylor Ford1, Jennifer Lane2, Michelle Noelck2

  • 1Emory University School of Medicine, Pediatric Hospital Medicine, Department of Pediatrics, Children's Healthcare of Atlanta, 1405 Clifton Road, Atlanta, GA 30322, United States.

Paediatric Respiratory Reviews
|June 27, 2024
PubMed
Summary

High flow nasal cannula (HFNC) use for bronchiolitis has risen, but evidence shows limited clinical benefit. This review covers HFNC

Keywords:
BronchiolitisCannulaHospitalizationHumansInfantOxygen

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Direct Tracheal Instillation of Solutes into Mouse Lung
04:50

Direct Tracheal Instillation of Solutes into Mouse Lung

Published on: August 29, 2010

29.2K

Related Experiment Videos

Last Updated: Jun 22, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Direct Tracheal Instillation of Solutes into Mouse Lung
04:50

Direct Tracheal Instillation of Solutes into Mouse Lung

Published on: August 29, 2010

29.2K

Area of Science:

  • Pediatrics
  • Respiratory Medicine
  • Critical Care

Background:

  • High flow nasal cannula (HFNC) therapy use for bronchiolitis has significantly increased over the past decade.
  • Despite widespread adoption, randomized controlled trials indicate minimal clinical benefit from early, routine HFNC use in bronchiolitis.

Purpose of the Study:

  • To provide a concise overview of the current clinical status of HFNC therapy for bronchiolitis.
  • To discuss effective de-implementation strategies aimed at reducing the overuse of HFNC.
  • To explore future considerations for quality improvement and research in pediatric bronchiolitis and HFNC management.

Main Methods:

  • Literature review of randomized controlled trials and clinical practice guidelines.
  • Analysis of trends in HFNC utilization for pediatric respiratory conditions.
  • Synthesis of expert recommendations on de-implementation and quality improvement.

Main Results:

  • Evidence suggests limited efficacy of routine early HFNC use in improving clinical outcomes for bronchiolitis.
  • Several successful de-implementation strategies have been identified to curb unnecessary HFNC application.
  • Future research should focus on optimizing HFNC use and improving quality of care.

Conclusions:

  • Overuse of HFNC in bronchiolitis is a concern, given the lack of demonstrated clinical benefit.
  • De-implementation strategies are crucial for optimizing resource allocation and patient care.
  • Continued research and quality improvement initiatives are necessary to refine HFNC protocols.